Abstract 1589P
Background
In addition to the structural/medical barriers that trial centres face in including patients, the disparities that patients face prevents some groups from receiving the expected benefit from the studies and the results from representing the entire population. This study assessed the barriers to recruiting individuals in phase one trials who were referred to clinical research facility located in central London.
Methods
Records of patients who were referred to Guy's Cancer Early Phase Trials Unit between January and December 2023 were retrospectively reviewed. Baseline patient characteristics and barriers to trial enrolment were recorded and descriptive statistics were presented. The distrubition of new referrals by age, cancer types, ethnicity, and socioeconomic status defined by Index of Multiple Deprivation (IMD,1 - most deprived; 10 - least deprived) was also assessed by comparing with our group's historic data published in 2013 in Journal of Clinical Oncology.
Results
We reviewed 206 new patients in 2023. Median age of the group was 63, and 52.4% of patient were male. GI, thoracic, gyneacological and urological malignancies were the most common tumour groups (37%, 19%, 18%, and 14% respectively). Of whole group, 33.9% of patients were referred after two lines of previous treatment. 37 patients (17.9%) were recruited to a trial annually. Most common barrier to be recruited to a trial is that the center has no potential trial to offer (N=59, 35.9%), followed by failure to meet radiological criteria (11.2%), and poor performance status (10.0%) 22 patients (10.6%) were from most deprivated (IMD 1-2) background. Our historic data from 2013 showed 21.9% of patients had been referred from most deprivated background. There was a white-ethnicitiy domination in current and historic data (71.5% and 74.2%, retrospectively).
Conclusions
An increasing number of new patients are being referred to our centre. Among the prominent recruitment barriers are the lack of appropriate studies and non-compliance with medical criteria. The decrease in the rate of patients from low socioeconomic backgrounds is striking compared to the historical data of our center. Further efforts should be made to identify the potential causes of this situation and to improve it.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1573P - Global cancer statistics for adolescents and young adults: New estimates from GLOBOCAN 2022
Presenter: Wang-Zhong Li
Session: Poster session 10
Resources:
Abstract
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10